The global demand for health supplements is booming, with the chondroitin sulfate ingredient alone valued at over $1.7 billion USD in a $7.8 billion supplement market, and projected to grow. However, a troubling truth underpins the chondroitin industry: it is sources from animal bones but 40% is sourced from shark cartilage due to its high chondroitin concentration compared to bovine or synthetic alternatives. This practice sees millions of wild sharks like Blue Sharks and Hammer Heads harvested annually, devastating marine ecosystems and alarming ethically-conscious consumers worldwide.
This critical issue creates a significant market opening. PhycoLife is strategically positioned with a scientifically validated, sustainably farmed seaweed alternative, delivering the important molecular structure found in shark cartilage without ecological devastation.
As consumer demand for ethical, plant-based solutions intensifies, PhycoLife has a clear pathway to capture a substantial share of this expanding multi-billion dollar market, offering potent innovations that heal people and our planet.
We are turning an environmental crisis into a frontier for biotech investment.
By Investing in PhycoLife, you're investing in a revenue-generating seaweed biotech leader disrupting a >$7.5B global supplements market.
Building on our proven model highlighted previously, PhycoLife's core strength lies in our comprehensive mastery of the entire seaweed value chain. We are not simply product sellers; we are fundamental creators, meticulously managing every stage from proprietary indoor marine cultivation and advanced bio-refining to the formulation of market-leading health products that meet stringent food and medical standards.
This end-to-end Australian-based supply chain control is crucial for our innovation, ensuring premium quality, traceability, and the rapid development of novel solutions.
Our commitment extends deeply into pioneering research and development. PhycoLife functions as a deep-tech innovation engine, actively driving glycobiology and marine biotechnology advancements that could lead to opportunities beyond what the market can see.
This R&D focus generates significant intellectual property, which underpins our unique ingredients like Phyaluronic™ (SXRG84) and our next-generation SeaFibre supplements. This integrated system of sustainable cultivation, controlled processing, and frontier science allows us to consistently deliver our diverse range of clinically validated supplements, bioactive skincare, and award-winning functional foods to a discerning market.
PhycoLife is strategically positioned within a rapidly expanding wellness landscape. Our initial targeted disruption is the ~$1.5 billion global shark cartilage supplement market (projected ~8.2% CAGR), offering a scientifically validated, ethical alternative to an ingredient that currently supplies 30-40% of the broader >$7.5 billion chondroitin sulfate supplements market. This precise entry point is just the beginning.
The global demand for sustainable, plant-based, and clinically proven health solutions is accelerating, creating enormous uplift. This trend directly fuels our international scaling strategy, particularly for the B2B supply of our proprietary seaweed ingredients to global nutraceutical, food and medical brands. Furthermore, our ongoing R&D in marine glycobiology continually unlocks significant growth opportunities across functional foods, advanced skincare, and new therapeutic applications.
PhycoLife is not just meeting current demand; we are building an innovation platform to lead within Australia's $2.3 billion NSW seaweed economy vision and the multitrillion dollar global wellness industry. NSW is well poised for real estate and resources to support this growth.
PhycoLife has achieved significant milestones, validating our business model and strong market demand. We proudly surpassed $1 million in revenue in FY25, driven by 160% annual sales growth and revenue tripling in the last six months alone. Our product efficacy and brand loyalty are confirmed by an exceptional ~60% customer retention rate and a customer base that more than doubled in the past year.
Operationally, we pioneered Australia’s first fully integrated seaweed value chain—from proprietary indoor cultivation and biorefining to creating novel ingredients like Phyaluronic™ that are clinically tested and that meet food grade standards. Our science is robust, with two pioneering human clinical trials published, leading to strong research partnerships across 4 universities and with numerous industry partners. This innovation and market leadership have garnered significant industry recognition, including multiple Australian Food Awards, "Most Innovative Protein Source" (International Food Expo London 2025), and prominent features in Forbes, BBC, and ABC.
These accomplishments showcase a de-risked, revenue-generating business primed for accelerated scaling.
PhycoLife’s competitive advantage is multi-layered and deeply entrenched, built on being Australia's pioneering, fully integrated seaweed biotech company.
Replicating our model is a formidable challenge due to the significant investment and specialised expertise required to master the entire value chain—from proprietary indoor cultivation and advanced bio-refining in Australia to creating medical-grade ingredients. This end-to-end sovereign control ensures unparalleled quality, traceability, and rapid innovation.
Crucially, we are an IP-generating, science-first company. Our deep expertise in marine glycobiology fuels a growing portfolio of proprietary ingredients like Phyaluronic™ and now Phychondrin™ . Our solutions are validated by two human clinical trials—a level of rigorous scientific backing rarely seen in this market.
This powerful fusion of a de-risked, scalable Australian supply chain, protected intellectual property, and proven product efficacy allows us to create truly unique, high-value offerings. Investors are backing a category leader with substantial barriers to entry, perfectly positioned to define the future where sustainable biotech meets scientifically proven health.
We want our shareholders to be as big fans of our products as we are, and to reap the health rewards. We are proud off offer a range of rewards for investment in the crowd equity campaign as follows:
Always consider the general CSF risk-warning and offer document before investing
Please note: Investments over $10,000 are restricted to Sophisticated investors - Apply here
Want to know more about equity crowdfunding? Click here